Combination Therapy with Androgen Deprivation for Hormone Sensitive Prostate Cancer: A New Frontier

Combination Therapy with Androgen Deprivation for Hormone Sensitive Prostate Cancer: A New Frontier

In the field of oncology, the treatment of prostate cancer has witnessed significant advancements in recent years. One such area that has gained attention is combination therapy with androgen deprivation for hormone-sensitive prostate cancer. This approach has opened up new frontiers in the fight against this deadly disease.

Androgen deprivation therapy (ADT) is a well-established treatment for prostate cancer. It works by reducing the levels of androgens, such as testosterone, in the body. This, in turn, inhibits the growth of prostate cancer cells. However, recent studies have shown that some tumor cells become quiescent after ADT and have the potential to reactivate.

One of the intriguing aspects of combination therapy with androgen deprivation is its impact on adenosine monophosphate-activated protein kinase (AMPK) activity. Androgen deprivation and tissue hypoxia, conditions that occur in prostate tissue after surgical or medical castration, lead to an increased AMPK activity in murine xenografts. This finding suggests that targeting AMPK could be a potential strategy for enhancing the efficacy of ADT.

Moreover, ADT induces various cell death mechanisms, including apoptosis, autophagy, necrosis, and necroptosis. Apoptosis, a form of programmed cell death, typically occurs early after ADT within the first 72 hours. This highlights the importance of early intervention and close monitoring during the initial stages of treatment.

The potential of combination therapy with androgen deprivation has been further explored in the clinical setting. The ARASTEP study, a phase 3 trial (NCT05794906), aims to evaluate the efficacy of darolutamide plus ADT in patients with high-risk biochemically recurrent (BCR) prostate cancer. The study will compare darolutamide plus ADT to placebo plus ADT, with a focus on radiological progression-free survival (rPFS) assessed by PSMA PET/CT. This study holds promise in providing valuable insights into the role of combination therapy in patients with BCR following primary therapy.

While the advancements in combination therapy with androgen deprivation are promising, it's essential to consider actionable advice for both healthcare professionals and patients. Here are three key takeaways:

1. Early intervention and close monitoring: As apoptosis typically occurs early after ADT, it is crucial for healthcare professionals to closely monitor patients during the initial stages of treatment. By identifying any signs of cell death, adjustments to the treatment plan can be made promptly.

2. Targeting AMPK: The increased AMPK activity observed after androgen deprivation suggests that targeting this protein could enhance the efficacy of ADT. Further research in this area may lead to the development of novel therapies that maximize the benefits of combination therapy.

3. Participating in clinical trials: Patients with high-risk BCR prostate cancer should consider participating in clinical trials like the ARASTEP study. By doing so, they contribute to the advancement of medical knowledge and gain access to potentially groundbreaking treatments.

In conclusion, combination therapy with androgen deprivation for hormone-sensitive prostate cancer represents a new frontier in the fight against this disease. With a deeper understanding of the mechanisms involved and ongoing clinical trials, there is hope for improved outcomes and enhanced treatment strategies. By implementing early intervention, targeting AMPK, and participating in clinical trials, we can continue to push the boundaries of prostate cancer treatment and provide better care for patients.